Maybe most/all of this is repeat. Not my writings,
Post# of 153778
(Total Views: 660)
Posted On: 11/19/2020 1:09:28 PM
Maybe most/all of this is repeat. Not my writings, stold from yahoo finance.
Submitted here in order to prompt some response.
There is a lot of shares outstanding and a lot of unused warrants right now. And don’t forget they are borrowing money for options (right term?) that convert at $10. I had a friend tell me that his brokerage said that they lent out his shares. As a result, Forces with lots of money can borrow a lot of shares snd and keep share price pinned down hoping CYDY runs out of money and are forced to take a deal. Most any other company that had a drug with so many uses in this stage of development would be in the $5-10B range. Basically the HIV indication is s lock because it blocks the co-receptor for HIV entry without disrupting all the signaling pathways CCR5 is attached to - unlike Maraviroc. I think this is why it has such a great safety profile. And a lot of diseases are the result of the inflammation response caused by an underlying problem (infection, graft rejection, Nash), throw in upregulation on metastic breast cancer cells...and you have CCR5 at the root of a lot of diseases. The Science behind the drug is great. The clinical trials have been going fast but not as fast as some inexperienced biotech investors would like. Don’t let the day to day stock fluctuations in stock price get u down. Think of it as an opportunity. I think the stock will be $100-200 once it gets EUAs for COVID s2c, longhaulers, m2m, HIV combo therapy and HIV monotherapy. If it works for breast cancer double that, if graft vs host and Nash are reduced with leronlimab your great grand kids will be thanking you for investing in CYDY. One near term note, don’t forget CYDY has issued a lot of convertible debt that converts at $10 so it’s going to be hard to break $10 for a while, but once it does, to the moon!
Submitted here in order to prompt some response.
There is a lot of shares outstanding and a lot of unused warrants right now. And don’t forget they are borrowing money for options (right term?) that convert at $10. I had a friend tell me that his brokerage said that they lent out his shares. As a result, Forces with lots of money can borrow a lot of shares snd and keep share price pinned down hoping CYDY runs out of money and are forced to take a deal. Most any other company that had a drug with so many uses in this stage of development would be in the $5-10B range. Basically the HIV indication is s lock because it blocks the co-receptor for HIV entry without disrupting all the signaling pathways CCR5 is attached to - unlike Maraviroc. I think this is why it has such a great safety profile. And a lot of diseases are the result of the inflammation response caused by an underlying problem (infection, graft rejection, Nash), throw in upregulation on metastic breast cancer cells...and you have CCR5 at the root of a lot of diseases. The Science behind the drug is great. The clinical trials have been going fast but not as fast as some inexperienced biotech investors would like. Don’t let the day to day stock fluctuations in stock price get u down. Think of it as an opportunity. I think the stock will be $100-200 once it gets EUAs for COVID s2c, longhaulers, m2m, HIV combo therapy and HIV monotherapy. If it works for breast cancer double that, if graft vs host and Nash are reduced with leronlimab your great grand kids will be thanking you for investing in CYDY. One near term note, don’t forget CYDY has issued a lot of convertible debt that converts at $10 so it’s going to be hard to break $10 for a while, but once it does, to the moon!
(3)
(0)